These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

513 related items for PubMed ID: 10385219

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo.
    Kwon D, Chae JB, Park CW, Kim YS, Lee SM, Kim EJ, Huh IH, Kim DY, Cho KD.
    Arzneimittelforschung; 2001; 51(3):204-13. PubMed ID: 11304936
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Differences in the antisecretory actions of the proton pump inhibitor AG-1749 (lansoprazole) and the histamine H2-receptor antagonist famotidine in rats and dogs.
    Nagaya H, Inatomi N, Satoh H.
    Jpn J Pharmacol; 1991 Apr; 55(4):425-36. PubMed ID: 1886288
    [Abstract] [Full Text] [Related]

  • 6. Biochemical and pharmacological properties of a newly synthesized proton pump (H+/K(+)-ATPase) inhibitor, TY-11345 in experimental animals.
    Yamaguchi T, Aihara K, Yamada S, Narita S, Kogi K.
    Jpn J Pharmacol; 1993 Aug; 62(4):363-71. PubMed ID: 8230863
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. General pharmacological properties of the new proton pump inhibitor (+/-)-5-methoxy-2-[[(4-methoxy-3,5-dimethylpyrid-2-yl)methyl]sulf inyl]- 1H-imidazo[4,5-b]pyridine.
    Kakinoki B, Ono C, Yamazaki N, Chikamatsu N, Wakatsuki D, Uchiyama K, Morinaka Y.
    Methods Find Exp Clin Pharmacol; 1999 Apr; 21(3):179-87. PubMed ID: 10389120
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Biochemical and pharmacological characteristics of 3-butyryl-8-methoxy-4-[(2-thiophenyl)amino]quinoline, a new proton-pump inhibitor, in rabbit gastric microsomes and in rats.
    Kim KB, Chang MS, Chung YK, Sohn SK, Kim SG, Choi WS.
    J Pharm Pharmacol; 1998 May; 50(5):521-9. PubMed ID: 9643446
    [Abstract] [Full Text] [Related]

  • 11. Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats.
    Satoh H, Inatomi N, Nagaya H, Inada I, Nohara A, Nakamura N, Maki Y.
    J Pharmacol Exp Ther; 1989 Feb; 248(2):806-15. PubMed ID: 2537418
    [Abstract] [Full Text] [Related]

  • 12. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases.
    Hori Y, Imanishi A, Matsukawa J, Tsukimi Y, Nishida H, Arikawa Y, Hirase K, Kajino M, Inatomi N.
    J Pharmacol Exp Ther; 2010 Oct; 335(1):231-8. PubMed ID: 20624992
    [Abstract] [Full Text] [Related]

  • 13. Characteristics of the K+-competitive H+,K+-ATPase inhibitor AZD0865 in isolated rat gastric glands.
    Kirchhoff P, Andersson K, Socrates T, Sidani S, Kosiek O, Geibel JP.
    Am J Physiol Gastrointest Liver Physiol; 2006 Nov; 291(5):G838-43. PubMed ID: 16798725
    [Abstract] [Full Text] [Related]

  • 14. Gastric antisecretory activity of lansoprazole in different experimental models: comparison with omeprazole.
    Coruzzi G, Adami M, Bertaccini G.
    Gen Pharmacol; 1995 Sep; 26(5):1027-32. PubMed ID: 7557245
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Antisecretory and antiulcer effect of T-330, a novel reversible proton pump inhibitor, in rats.
    Kinoshita M, Saito N, Tamaki H.
    Eur J Pharmacol; 1997 Mar 05; 321(3):325-32. PubMed ID: 9085044
    [Abstract] [Full Text] [Related]

  • 17. Current status of acid pump antagonists (reversible PPIs).
    Wurst W, Hartmann M.
    Yale J Biol Med; 1996 Mar 05; 69(3):233-43. PubMed ID: 9165692
    [Abstract] [Full Text] [Related]

  • 18. The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion.
    Blum RA, Shi H, Karol MD, Greski-Rose PA, Hunt RH.
    Clin Ther; 1997 Mar 05; 19(5):1013-23. PubMed ID: 9385488
    [Abstract] [Full Text] [Related]

  • 19. Characterization of the inhibitory activity of tenatoprazole on the gastric H+,K+ -ATPase in vitro and in vivo.
    Shin JM, Homerin M, Domagala F, Ficheux H, Sachs G.
    Biochem Pharmacol; 2006 Mar 14; 71(6):837-49. PubMed ID: 16405921
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of the effect of lansoprazole in suppressing acid secretion using 24-hour intragastric pH monitoring.
    Takeda H, Hokari K, Asaka M.
    J Clin Gastroenterol; 1995 Mar 14; 20 Suppl 1():S7-9. PubMed ID: 7673616
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.